Cidara Therapeutics Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of Cidara Therapeutics Inc Company

Cidara Therapeutics, Inc. is a biotechnology company. The Company is developing targeted immunotherapies designed for patients facing serious diseases. The Company’s portfolio comprises various treatment and prevention paradigms, including drug-Fc conjugate (DFC) from its Cloudbreak platform targeting oncologic, viral and autoimmune diseases. The Company is focused on advancing Cloudbreak development programs, including its lead oncology candidate, CBO421, as well as advancing other pipeline assets. CBO421 is a development candidate targeting CD73 for the treatment of solid tumors. Its advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials. Its additional programs target multiple autoimmune indications.

Cidara Therapeutics Inc Info



Ticker SymbolCDTX

Company nameCidara Therapeutics Inc

IPO dateApr 15, 2015

CEODr. Jeffrey L. (Jeff) Stein, Ph.D.

Number of employees38

Security typeOrdinary Share

Fiscal year-endApr 15

Address6310 Nancy Ridge Dr Ste 101

CitySAN DIEGO

Stock exchangeNASDAQ Capital Market Consolidated

CountryUnited States of America

Postal code92121-3209

Phone18587526170

Websitehttps://www.cidara.com/

Ticker SymbolCDTX

IPO dateApr 15, 2015

CEODr. Jeffrey L. (Jeff) Stein, Ph.D.

Company Executives of Cidara Therapeutics Inc



Name

Name/Position

Position

Shareholding

Change

Mr. Frank L. Karbe

Chief Financial Officer

57.50K

--

Mr. Daniel D. (Dan) Burgess

Independent Chairman of the Board

150.00

--

Mr. Ryan Spencer

Independent Director

--

Dr. Bonnie Bassler, Ph.D.

Independent Director

--

Ms. Chrysa Mineo

Independent Director

--

Dr. Jeffrey L. (Jeff) Stein, Ph.D.

President, Chief Executive Officer, Director

--

Mr. Brian Ritchie

Investor Relations

--

Mr. Theodore R. (Ted) Schroeder

Independent Director

--

Mr. Shane Ward

Chief Operating Officer, Chief Legal Officer, Company Secretary

--

Dr. Josh Resnick, M.D., J.D.

Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Mr. Frank L. Karbe

Chief Financial Officer

57.50K

--

Mr. Daniel D. (Dan) Burgess

Independent Chairman of the Board

150.00

--

Mr. Ryan Spencer

Independent Director

--

Dr. Bonnie Bassler, Ph.D.

Independent Director

--

Ms. Chrysa Mineo

Independent Director

--

Dr. Jeffrey L. (Jeff) Stein, Ph.D.

President, Chief Executive Officer, Director

--

Revenue Breakdown

No Data

No Data

By Business

By Region

No Data

Shareholding Stats

Updated: Fri, Oct 31

Shareholders

Shareholder Types

Shareholders

Proportion

RA Capital Management, LP

10.70%

Bain Capital Life Sciences Investors, LLC

7.95%

Point72 Asset Management, L.P.

4.86%

Vivo Capital, LLC

4.17%

The Vanguard Group, Inc.

3.91%

Other

68.40%

Shareholders

Proportion

RA Capital Management, LP

10.70%

Bain Capital Life Sciences Investors, LLC

7.95%

Point72 Asset Management, L.P.

4.86%

Vivo Capital, LLC

4.17%

The Vanguard Group, Inc.

3.91%

Other

68.40%

Shareholder Types

Shareholders

Proportion

Hedge Fund

40.25%

Investment Advisor

26.13%

Venture Capital

22.74%

Investment Advisor/Hedge Fund

18.53%

Research Firm

4.33%

Individual Investor

0.89%

Pension Fund

0.09%

Bank and Trust

0.08%

Private Equity

0.06%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

223

28.87M

92.92%

+14.12M

2025Q2

140

15.92M

78.58%

+7.99M

2025Q1

124

10.47M

53.54%

+2.71M

2024Q4

122

7.70M

70.35%

+1.07M

2024Q3

109

4.49M

61.04%

+771.77K

2024Q2

109

1.90M

39.70%

+56.88K

2024Q1

108

1.55M

384.06%

-209.94K

2023Q4

111

1.70M

37.69%

-299.58K

2023Q3

119

1.90M

42.77%

-451.34K

2023Q2

126

1.95M

43.98%

-451.51K

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

RA Capital Management, LP

3.37M

13.27%

--

Aug 07, 2025

Bain Capital Life Sciences Investors, LLC

2.50M

9.86%

+1.80M

+255.68%

Jun 30, 2025

Point72 Asset Management, L.P.

1.53M

6.03%

+528.52K

+52.88%

Jun 30, 2025

Vivo Capital, LLC

1.31M

5.17%

+627.15K

+91.65%

Jun 30, 2025

The Vanguard Group, Inc.

966.71K

3.81%

+457.13K

+89.71%

Jun 30, 2025

BVF Partners L.P.

786.39K

3.1%

-138.25K

-14.95%

Jun 30, 2025

Commodore Capital LP

1.18M

4.63%

+1.18M

--

Jun 30, 2025

Paradigm BioCapital Advisors LP

1.13M

4.45%

+1.13M

--

Jul 23, 2025

Adage Capital Management, L.P.

1.10M

4.34%

+110.00K

+11.11%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

1.02M

4.03%

+974.57K

+2030.95%

Jun 30, 2025

Related ETFs



Updated: Thu, Nov 6

Name

Proportion

Invesco Dorsey Wright Healthcare Momentum ETF

3.64%

Invesco Dorsey Wright SmallCap Momentum ETF

1.39%

SPDR S&P Biotech ETF

0.77%

Direxion Daily S&P Biotech Bull 3X Shares

0.41%

Even Herd Long Short ETF

0.39%

iShares Micro-Cap ETF

0.28%

VictoryShares US Small Mid Cap Value Momentum ETF

0.25%

Vanguard US Momentum Factor ETF

0.23%

iShares Russell 2000 Value ETF

0.1%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

0.09%

Invesco Dorsey Wright Healthcare Momentum ETF

Proportion3.64%

Invesco Dorsey Wright SmallCap Momentum ETF

Proportion1.39%

SPDR S&P Biotech ETF

Proportion0.77%

Direxion Daily S&P Biotech Bull 3X Shares

Proportion0.41%

Even Herd Long Short ETF

Proportion0.39%

iShares Micro-Cap ETF

Proportion0.28%

VictoryShares US Small Mid Cap Value Momentum ETF

Proportion0.25%

Vanguard US Momentum Factor ETF

Proportion0.23%

iShares Russell 2000 Value ETF

Proportion0.1%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

Proportion0.09%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

Apr 22, 2024

Merger

20→1

Apr 22, 2024

Merger

20→1

Apr 22, 2024

Merger

20→1

Apr 22, 2024

Merger

20→1

Date

Type

Ratio

Apr 22, 2024

Merger

20→1

Apr 22, 2024

Merger

20→1

Apr 22, 2024

Merger

20→1

Apr 22, 2024

Merger

20→1